Pilot Study of Diagnostic Potential of the Mycobacterium tuberculosis Recombinant HBHA Protein in a Vaccinated Population in Finland
2008

Diagnostic Potential of Mycobacterium tuberculosis HBHA Protein in Finland

Sample size: 30 publication Evidence: low

Author Information

Author(s): Laura Savolainen, Liana Pusa, Hwa-Jung Kim, Heidi Sillanpää, Ilkka Seppälä, Tamara Tuuminen

Primary Institution: University of Helsinki

Hypothesis

Can the recombinant HBHA protein effectively differentiate between active and latent tuberculosis infections in a vaccinated population?

Conclusion

The study suggests that HBHA may not be a sufficient diagnostic tool for tuberculosis in populations with high BCG vaccination rates.

Supporting Evidence

  • HBHA induced a strong immune response in all patient groups, including vaccinated individuals.
  • ESAT-6 and CFP-10 were more effective at distinguishing between disease and immunity than HBHA.
  • High interindividual variation in immune responses was observed across all groups.

Takeaway

Researchers wanted to see if a specific protein from tuberculosis could help tell if someone has the disease or just had a vaccine, but it didn't work as well as hoped.

Methodology

The study compared immune responses to recombinant HBHA and other proteins in patients with tuberculosis and vaccinated individuals using ELISPOT and EIA techniques.

Potential Biases

Potential bias due to the high vaccination coverage in the population studied.

Limitations

The study had a small sample size and did not include a group of patients with proven latent tuberculosis infection.

Participant Demographics

Participants included active TB patients, inactive TB patients, individuals with atypical mycobacteriosis, and healthy vaccinated individuals, primarily Finnish.

Digital Object Identifier (DOI)

10.1371/journal.pone.0003272

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication